Shankar Siva about the results of DESTROY-2 trial
Shankar Siva, Radiation Oncologist at Peter MacCallum Cancer Centre, shared a post on X about a recent paper by F. Deodato et al. published in Clinical Oncology.
“DESTROY-2 trial. A quick reminder to those who worry about side effects with single fraction SABR – only 1x Grade 3 adverse event after 227 courses of stereotactic body radiotherapy. It can be done safely!”
Michael Chuong, Professor at Florida International University’s Herbert Wertheim College of Medicine, shared this post, adding:
“Our ph2 SMART ONE trial (mostly liver, adrenal, abdominal LN, 25-40 Gy x 1) also showed:
- Safety: only 1 possibly related Gr3 AE
- Efficacy: 1-yr LC 100%
- Manuscript submission pending
Working on some interesting single fraction SABR trial concepts…stay tuned.”
Authors: F. Deodato, D. Pezzulla, S. Cilla, C. Romano, Mi. Ferro, E. Galietta, V. Lancellotta, A.G. Morganti, G. Macchia
More posts featuring Shankar Siva and Michael Chuong.
Michael Chuong is the GI Section Editor for the International Journal of Radiation Oncology Biology Physics. He is a Professor at Florida International University’s Herbert Wertheim College of Medicine and serves as the Vice Chair and Medical Director of the Department of Radiation Oncology at the Miami Cancer Institute.
Additionally, he is the Chief of the GI Radiation Oncology Service at Baptist Health South Florida, specializing in the treatment of gastrointestinal cancers.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023